Bank Pictet & Cie Europe AG Has $12.44 Million Stock Position in Abbott Laboratories $ABT

Bank Pictet & Cie Europe AG reduced its position in Abbott Laboratories (NYSE:ABT) by 15.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 91,495 shares of the healthcare product maker’s stock after selling 16,732 shares during the period. Bank Pictet & Cie Europe AG’s holdings in Abbott Laboratories were worth $12,444,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Brave Asset Management Inc. increased its position in Abbott Laboratories by 1.8% in the 2nd quarter. Brave Asset Management Inc. now owns 5,694 shares of the healthcare product maker’s stock worth $774,000 after purchasing an additional 100 shares during the last quarter. MKT Advisors LLC acquired a new position in Abbott Laboratories in the 2nd quarter worth about $212,000. MBE Wealth Management LLC increased its position in Abbott Laboratories by 11.8% in the 2nd quarter. MBE Wealth Management LLC now owns 4,919 shares of the healthcare product maker’s stock worth $669,000 after purchasing an additional 518 shares during the last quarter. Old North State Wealth Management LLC acquired a new position in Abbott Laboratories in the 2nd quarter worth about $231,000. Finally, Register Financial Advisors LLC increased its position in Abbott Laboratories by 49.5% in the 2nd quarter. Register Financial Advisors LLC now owns 3,590 shares of the healthcare product maker’s stock worth $488,000 after purchasing an additional 1,188 shares during the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Stock Performance

ABT opened at $133.38 on Friday. The firm has a market capitalization of $232.13 billion, a P/E ratio of 16.71, a price-to-earnings-growth ratio of 2.54 and a beta of 0.69. The stock’s 50 day moving average price is $130.94 and its two-hundred day moving average price is $131.14. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. Abbott Laboratories has a 12-month low of $110.86 and a 12-month high of $141.23.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.26. The firm had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The company’s revenue was up 7.4% on a year-over-year basis. During the same quarter last year, the firm posted $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, equities analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be given a $0.59 dividend. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 29.57%.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the firm’s stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the sale, the chief financial officer owned 51,003 shares in the company, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.46% of the company’s stock.

Analyst Upgrades and Downgrades

ABT has been the topic of several research reports. Mizuho upped their target price on Abbott Laboratories from $130.00 to $140.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 16th. BTIG Research decreased their price target on Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating for the company in a research note on Friday, July 18th. Morgan Stanley upped their price target on Abbott Laboratories from $127.00 to $137.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 15th. Leerink Partnrs upgraded Abbott Laboratories to a “hold” rating in a research note on Monday, June 16th. Finally, Royal Bank Of Canada upped their price target on Abbott Laboratories from $145.00 to $147.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 15th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $145.22.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.